However, since the tumor can develop secondary mutations of EGFR and other oncogenes, and from the fact that a relevant percentage of metastatic locations differs in genetic expression from the primitive disease, predicting tumor responses solely by the presence of specific mutations is not entirely reliable. The gene discussed is EGFR; the disease is neoplasm.